北京大学医学部机构知识库
Advanced  
IR@PKUHSC  > 北京大学第一临床医学院  > 心血管内科  > 期刊论文
学科主题: 临床医学
题名:
CYP2C9 Ile359Leu polymorphism, plasma irbesartan concentration and acute blood pressure reductions in response to irbesartan treatment in Chinese hypertensive patients
作者: Chen, G1; Jiang, S1; Mao, G1; Zhang, S1; Hong, X1; Tang, G1; Li, Z1; Liu, X1; Zhang, Y1; Xing, H1; Wang, B1; Yu, Y1; Xu, X1
关键词: blood pressure ; CYP2C9 gene ; drug concentration ; gene polymorphism ; irbesartan ; pharmacogenetics
刊名: METHODS AND FINDINGS IN EXPERIMENTAL AND CLINICAL PHARMACOLOGY
发表日期: 2006
DOI: 10.1358/mf.200628.1.962773
卷: 28, 期:1, 页:19-24
收录类别: SCI
文章类型: Article
WOS标题词: Science & Technology
类目[WOS]: Pharmacology & Pharmacy
研究领域[WOS]: Pharmacology & Pharmacy
关键词[WOS]: II RECEPTOR ANTAGONIST ; GENETIC-POLYMORPHISM ; LIVER-MICROSOMES ; ALLELIC VARIANTS ; CYP2C9 ; POPULATION ; CYP2C9-ASTERISK-3 ; CYTOCHROME-P450 ; WARFARIN ; ASSOCIATION
英文摘要:

Our previous study demonstrated that the CYP2C9*3 gene variant was significantly associated with elevated plasma irbesartan concentration and blood pressure decline, assessed by a 4-week follow-up and revisit following daily administration of irbesartan. We conducted a further analysis to examine the acute effects of the CYP2C9 polymorphism on plasma concentration and blood pressure through remeasurement 6 h after administration of irbesartan. We used an extreme-sampling approach by selecting individuals from the top and bottom deciles of blood pressure response residuals to irbesartan from the previous study population in Anhui, Taihu, and Dongzhi Counties, in China. A total of 196 subjects were available for the analysis. Pre- and posttreatment systolic and diastolic blood pressures (SBP and DBP), and venous blood samples (0.5, 2, and 6 h following the first treatment) were collected from each individual. Plasma irbesartan concentrations were determined by a standard HPLC/fluorescence method. the observed frequencies were 97.7% for CYP2C9*1 (Ile358) and 2.3% for CYP2C9*3 (Leu359). Subjects with the CYP2C9*1/CYP2C9*3 genotype had significantly higher plasma irbesartan concentrations when compared with those with the CYP2C9*1/CYP2C9*1 genotype (beta +/- SE = 81 +/- 36) and greater DBP response (beta +/- SE = 5.6 +/- 2.5 mmHg) at the 6-h time point after adjusting for important confounders. Our finding suggests that the CYP2C9*3 gene variant significantly alters the plasma concentration and acute DBP response at the 6-h point following irbesartan treatment in Chinese hypertensive patients. (C) 2006 Prous Science. All rights reserved.

语种: 英语
WOS记录号: WOS:000236340900004
Citation statistics:
内容类型: 期刊论文
URI标识: http://ir.bjmu.edu.cn/handle/400002259/53119
Appears in Collections:北京大学第一临床医学院_心血管内科_期刊论文

Files in This Item:

There are no files associated with this item.


作者单位: 1.Anhui Coll Tradit Chinese Med, Dept Pharmacol, Hefei, Peoples R China
2.Anhui Med Univ, Inst Biomed, Hefei 230032, Anhui, Peoples R China
3.Univ Sci & Technol China, Sch Life Sci, Hefei 230026, Peoples R China
4.Peking Univ, Hosp 1, Dept Cardiovasc Dis, Beijing 100871, Peoples R China

Recommended Citation:
Chen, G,Jiang, S,Mao, G,et al. CYP2C9 Ile359Leu polymorphism, plasma irbesartan concentration and acute blood pressure reductions in response to irbesartan treatment in Chinese hypertensive patients[J]. METHODS AND FINDINGS IN EXPERIMENTAL AND CLINICAL PHARMACOLOGY,2006,28(1):19-24.
Service
Recommend this item
Sava as my favorate item
Show this item's statistics
Export Endnote File
Google Scholar
Similar articles in Google Scholar
[Chen, G]'s Articles
[Jiang, S]'s Articles
[Mao, G]'s Articles
CSDL cross search
Similar articles in CSDL Cross Search
[Chen, G]‘s Articles
[Jiang, S]‘s Articles
[Mao, G]‘s Articles
Related Copyright Policies
Null
Social Bookmarking
Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit

Items in IR are protected by copyright, with all rights reserved, unless otherwise indicated.

 

 

Valid XHTML 1.0!
Copyright © 2007-2017  北京大学医学部 - Feedback
Powered by CSpace